This information is intended for healthcare professionals based in Belgium and Luxembourg.
If you are not a healthcare professional, click here

Opdivo_Yervoy_Logo Opdivo_Yervoy_Logo Opdivo_Logo Opdivo_Chemotherapy_Logo

Adjuvant esophageal (EC or GEJC)

OPDIVO, THE ONLY IMMUNOTHERAPY AVAILABLE ACROSS ALL LINES AND HISTOLOGIES OF UPPER GI PATIENTS

Opdivo + Yervoy in ESCC 1L is not currently reimbursed in Belgium.

View indication details

  • OPDIVO as monotherapy is indicated for the adjuvant treatment of adult patients with oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy.
  • OPDIVO in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma whose tumours express PD-L1 with a combined positive score (CPS) ≥ 5.
  • OPDIVO in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression ≥ 1%.
  • OPDIVO in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression ≥ 1%.
  • OPDIVO as monotherapy is indicated for the treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based combination chemotherapy.
Expert opinion

NEW

recommendations
in upper GI

NEW

A PD-L1 debate among pathologists:
Emerging trends on PD-L1 testing in MIUC
and Upper GI cancers

Upper GI and CPS:
A Ping Pong game between
a Pathologist and an Oncologist

Product information

PD-L1 testing
overview for OPDIVO

Dosing schemes
OPDIVO in GI cancers

Practical user guide
based on OPDIVO SmPC

Patient & nurse materials

Patient brochure
with practical information
on immunotherapy

www.immunooncology.be

An informative website
on immunotherapy
for your nurses

Patient alert card

irAE(s), immune-related adverse event(s)